| Literature DB >> 29760555 |
Qiaowei Fan1,2, Bingrong Liu1.
Abstract
PURPOSE: This study was aimed to develop a lncRNA-associated competing endogenous RNA (ceRNA) network to provide further understanding of the ceRNA regulatory mechanism and pathogenesis in colorectal cancer (CRC). PATIENTS AND METHODS: Expression profiles of mRNAs, lncRNAs, and miRNAs, and clinical information for CRC patients were obtained from The Cancer Genome Atlas. The differentially expressed mRNAs, lncRNAs, and miRNAs (referred to as "DEmRNAs", "DElncRNAs", and "DEmiRNAs", respectively) were screened out between 539 CRC samples and 11 normal samples. The interactions between DElncRNAs and DEmiRNAs were predicted by miRcode. The DEmRNAs targeted by the DEmiRNAs were retrieved according to TargetScan, miRTar-Base, and miRDB. The lncRNA-miRNA-mRNA ceRNA network was constructed based on the DEmiRNA-DElncRNA and DEmiRNA-DEmRNA interactions. Functional enrichment analysis revealed the biological processes and pathways of DEmRNAs involved in the development of CRC. Key lncRNAs were further analyzed for their associations with overall survival and clinical features of CRC patients.Entities:
Keywords: colorectal cancer; competing endogenous RNA network; long noncoding RNA; survival analysis
Year: 2018 PMID: 29760555 PMCID: PMC5937496 DOI: 10.2147/OTT.S158309
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Clinicopathological characteristics of 539 CRC patients
| Clinicopathological characteristics | Patients (N=539)
| |
|---|---|---|
| n | % | |
| Age category (years) | ||
| <65 | 220 | 40.82 |
| ≥65 | 319 | 59.18 |
| Gender | ||
| Female | 252 | 46.75 |
| Male | 287 | 53.25 |
| Pathological stage | ||
| Stage I | 99 | 18.37 |
| Stage II | 192 | 35.62 |
| Stage III | 163 | 30.24 |
| Stage IV | 85 | 15.77 |
| Pathologic T | ||
| Tis | 1 | 0.18 |
| T1 | 18 | 3.34 |
| T2 | 95 | 17.63 |
| T3 | 360 | 66.79 |
| T4 | 65 | 12.06 |
| Pathologic N | ||
| N0 | 301 | 55.85 |
| N1 | 138 | 25.60 |
| N2 | 100 | 18.55 |
| Pathologic M | ||
| M0 | 404 | 74.95 |
| M1 | 83 | 15.40 |
| Mx | 52 | 9.65 |
| Survival status | ||
| Alive | 440 | 81.63 |
| Dead | 99 | 18.37 |
Abbreviation: CRC, colorectal cancer.
Figure 1Flowchart of the lncRNA–miRNA–mRNA ceRNA network analysis.
Figure 2Heatmaps based on the differentially expressed RNAs in CRC and normal tissues.
Notes: (A) The heatmap with top 100 upregulated and top 100 downregulated mRNAs. (B) The heatmap with top 100 upregulated and top 100 downregulated lncRNAs. (C) The heatmap with all the DEmiRNAs.
Abbreviation: CRC, colorectal cancer.
The top 11 DElncRNAs putatively targeted by most DEmiRNAs in the ceRNA network
| DElncRNAs | DEmiRNAs |
|---|---|
| KCNQ1OT1 | hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-182, hsa-mir-192, hsa-mir-193b, hsa-mir-206, hsa-mir-217, hsa-mir-223, hsa-mir-301b, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-375, hsa-mir-424, hsa-mir-429, hsa-mir-454, hsa-mir-96, hsa-mir-98 |
| ADAMTS9-AS2 | hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-182, hsa-mir-193b, hsa-mir-223, hsa-mir-301b, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-375, hsa-mir-454, hsa-mir-96, hsa-mir-98 |
| DLX6-AS1 | hsa-mir-106a, hsa-mir-141, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-192, hsa-mir-193b, hsa-mir-206, hsa-mir-223, hsa-mir-338, hsa-mir-372, hsa-mir-424, hsa-mir-429 |
| AGAP11 | hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-182, hsa-mir-193b, hsa-mir-206, hsa-mir-21, hsa-mir-217, hsa-mir-372, hsa-mir-375, hsa-mir-424 |
| AC010336.2 | hsa-mir-106a, hsa-mir-141, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-17, hsa-mir-182, hsa-mir-192, hsa-mir-193b, hsa-mir-338, hsa-mir-372, hsa-mir-429 |
| LINC00461 | hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-144, hsa-mir-145, hsa-mir-150, hsa-mir-192, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-424, hsa-mir-96 |
| LINC00484 | hsa-mir-106a, hsa-mir-141, hsa-mir-143, hsa-mir-152, hsa-mir-206, hsa-mir-217, hsa-mir-223, hsa-mir-32, hsa-mir-338, hsa-mir-372, hsa-mir-424, hsa-mir-98 |
| LIFR-AS1 | hsa-mir-106a, hsa-mir-144, hsa-mir-150, hsa-mir-182, hsa-mir-192, hsa-mir-193b, hsa-mir-206, hsa-mir-32, hsa-mir-372, hsa-mir-375, hsa-mir-96 |
| LINC00330 | hsa-mir-106a, hsa-mir-145, hsa-mir-150, hsa-mir-17, hsa-mir-192, hsa-mir-206, hsa-mir-301b, hsa-mir-372, hsa-mir-424, hsa-mir-454, hsa-mir-98 |
| FAM95B1 | hsa-mir-141, hsa-mir-143, hsa-mir-150, hsa-mir-152, hsa-mir-182, hsa-mir-206, hsa-mir-338, hsa-mir-375, hsa-mir-96, hsa-mir-98 |
| PVT1 | hsa-mir-106a, hsa-mir-143, hsa-mir-145, hsa-mir-150, hsa-mir-152, hsa-mir-17, hsa-mir-21, hsa-mir-217, hsa-mir-372, hsa-mir-424 |
The 25 DEmiRNAs with their target DEmRNAs in the ceRNA network
| DEmiRNAs | DEmRNAs |
|---|---|
| hsa-mir-106a | CFL2, FOXQ1, FAM129A, CADM2, FJX1 |
| hsa-mir-141 | ELAVL4, PHLPP2, EPHA7, KIAA1549 |
| hsa-mir-143 | COL1A1, SERPINE1 |
| hsa-mir-144 | KCNQ5, GRIK3 |
| hsa-mir-145 | SERPINE1 |
| hsa-mir-150 | EREG, HILPDA, SLC7A11 |
| hsa-mir-152 | BMP3, NPTX1, KLF4 |
| hsa-mir-17 | FAM46C, FOXQ1, FJX1, CADM2, CYBRD1, FAM129A, CFL2 |
| hsa-mir-182 | CHL1, NPTX1, ULBP2 |
| hsa-mir-192 | GRHL1 |
| hsa-mir-193b | PLAU |
| hsa-mir-206 | STC2, SFRP1 |
| hsa-mir-21 | TGFBI |
| hsa-mir-217 | DACH1 |
| hsa-mir-223 | EPB41L3 |
| hsa-mir-301b | RBM20, CFL2 |
| hsa-mir-32 | PHLPP2, PBLD, PAX9, UGP2 |
| hsa-mir-338 | NOVA1 |
| hsa-mir-372 | CADM2, TMEM100, SLC7A11, MIXL1 |
| hsa-mir-375 | ELAVL4 |
| hsa-mir-424 | PSAT1, TMEM100, PHLPP2, CBX2, AXIN2, TPM2 |
| hsa-mir-429 | PMAIP1 |
| hsa-mir-454 | CFL2, RBM20 |
| hsa-mir-96 | ALK, TRIB3, SLC1A1 |
| hsa-mir-98 | HAND1, IGF2BP1, PRSS22, RGS16, TRIM71, IGF2BP3, CPA4 |
Figure 3The lncRNA–miRNA–mRNA ceRNA network in CRC.
Notes: Red rounds represent upregulated DEmRNAs and blue rounds represent downregulated DEmRNAs. Red squares represent upregulated DElncRNAs and blue squares represent downregulated DElncRNAs. Green triangles represent upregulated DEmiRNAs and yellow triangles represent downregulated DEmiRNAs.
Abbreviation: CRC, colorectal cancer.
Figure 4Linear regression of ceRNA expression levels for LINC00461.
Notes: LINC00461 vs (A) CADM2, (B) GRIK3, (C) ELAVL4, (D) FAM129A, (E) CFL2, (F) TMEM100, (G) NOVA1, (H) TPM2, and (I) MIXL1. The red line represents the linear model fitted by the dots in each figure, while green lines represent the 95% CI. “Cor” represents the correlation between the expressions of LINC00461 and the specific mRNA.
Figure 5Linear regression of ceRNA expression levels for LINC00484.
Notes: LINC00484 vs (A) BMP3, (B) UGP2, (C) PHLPP2, (D) KLF4, (E) PBLD, (F) EPB41L3, (G) TMEM100, and (H) SFRP1. The red line represents the linear model fitted by the dots in each figure while green lines represent the 95% CI. “Cor” represents the correlation between the expressions of LINC00484 and the specific mRNA.
Figure 6Kaplan–Meier survival curves for the two DElncRNAs significantly associated with overall survival of CRC patients. Note: Kaplan–Meier survival curves for (A) AP004609.1 and (B) C2orf48.
Abbreviation: CRC, colorectal cancer.
Figure 7Kaplan–Meier survival curves for the five DEmiRNAs significantly associated with overall survival of CRC patients.
Note: Kaplan–Meier survival curves for (A) hsa-mir-96, (B) hsa-mir-144, (C) hsa-mir-145, (D) hsa-mir-193b, and (E) hsa-mir-375.
Abbreviation: CRC, colorectal cancer.
Figure 8Kaplan–Meier survival curves for the six DEmRNAs significantly associated with overall survival of CRC patients.
Note: Kaplan–Meier survival curves for (A) FAM46C, (B) FJX1, (C) HAND1, (D) SERPINE1, (E) TPM2, and (F) ULBP2.
Abbreviation: CRC, colorectal cancer.
The correlations between DElncRNAs from the ceRNA network and clinical features of CRC patients
| Comparisons | Upregulated | Downregulated |
|---|---|---|
| Gender (male vs female) | AC110491.1 | |
| N stage (N1 + N2 vs N0) | H19 | HULC |
| M stage (M1 vs M0) | CLDN10-AS1, H19 | HULC |
| Pathological stage (III + IV vs I + II) | H19 | HULC |
Abbreviation: CRC, colorectal cancer.
The top 10 predominant BP terms and all the four CC terms and MF terms in GO functional enrichment analysis
| Categories | Terms | Count | |
|---|---|---|---|
| GO BP | GO:0045892~negative regulation of transcription, DNA-templated | 7 | 3.16 E–03 |
| GO:0048147~negative regulation of fibroblast proliferation | 3 | 3.68 E–03 | |
| GO:0001525~angiogenesis | 5 | 4.02 E–03 | |
| GO:0043434~response to peptide hormone | 3 | 7.30 E–03 | |
| GO:0071363~cellular response to growth factor stimulus | 3 | 7.62 E–03 | |
| GO:0050680~negative regulation of epithelial cell proliferation | 3 | 0.012 | |
| GO:0017148~negative regulation of translation | 3 | 0.012 | |
| GO:0001957~intramembranous ossification | 2 | 0.017 | |
| GO:0042035~regulation of cytokine biosynthetic process | 2 | 0.020 | |
| GO:0060346~bone trabecula formation | 2 | 0.023 | |
| GO CC | GO:0005615~extracellular space | 13 | 1.79 E–04 |
| GO:0070062~extracellular exosome | 14 | 0.031 | |
| GO:0005886~plasma membrane | 18 | 0.036 | |
| GO:0031012~extracellular matrix | 4 | 0.045 | |
| GO MF | GO:0003730~mRNA 3′-UTR binding | 3 | 8.90 E–03 |
| GO:0045182~translation regulator activity | 2 | 0.017 | |
| GO:0048027~mRNA 5′-UTR binding | 2 | 0.026 | |
| GO:0001190~transcriptional activator activity, RNA polymerase II transcription factor binding | 2 | 0.045 |
Abbreviations: BP, biological process; CC, cellular component; GO, Gene Ontology; MF, molecular function; UTR, untranslated region.
KEGG pathways enriched by the DEmRNAs in the ceRNA network
| ID | Terms | |
|---|---|---|
| hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3.51 E–03 |
| hsa04115 | p53 signaling pathway | 9.51 E–03 |
| hsa04610 | Complement and coagulation cascades | 0.012 |
| hsa00750 | Vitamin B6 metabolism | 0.014 |
| hsa04974 | Protein digestion and absorption | 0.016 |
| hsa05206 | MicroRNAs in cancer | 0.019 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 0.020 |
| hsa04724 | Glutamatergic synapse | 0.024 |
| hsa04310 | Wnt signaling pathway | 0.036 |
| hsa04390 | Hippo signaling pathway | 0.041 |
Abbreviation: KEGG, Kyoto Encyclopedia of Genes and Genomes.
All the 64 DElncRNAs in the ceRNA network
| DElncRNAs | Ensembl ID | Log2FC | FDR | DElncRNAs | Ensembl ID | Log2FC | FDR |
|---|---|---|---|---|---|---|---|
| ABCA9-AS1 | ENSG00000231749 | 3.9864 | 1.50E–03 | ERVMER61-1 | ENSG00000230426 | 6.2730 | 4.00E–03 |
| AC007384.1 | ENSG00000237513 | −2.4205 | 6.92E–14 | FAM95B1 | ENSG00000223839 | −2.0743 | 4.64E–06 |
| AC009065.1 | ENSG00000259780 | 2.4120 | 7.23E–03 | FRMD6-AS2 | ENSG00000258537 | −3.1025 | 7.09E–09 |
| AC009093.1 | ENSG00000259807 | 3.0580 | 8.28E–05 | GAS6-AS1 | ENSG00000233695 | 3.5499 | 1.09E–07 |
| AC009336.1 | ENSG00000272729 | −2.0597 | 6.03E–06 | H19 | ENSG00000130600 | 4.1017 | 5.86E–04 |
| AC010336.2 | ENSG00000260500 | −2.7897 | 2.57E–14 | HCG23 | ENSG00000228962 | −2.5508 | 3.36E–13 |
| AC012640.1 | ENSG00000248968 | 2.4459 | 2.90E–04 | HULC | ENSG00000251164 | 6.8799 | 6.67E–03 |
| AC016745.1 | ENSG00000234997 | 3.6141 | 4.61E–03 | JAZF1-AS1 | ENSG00000234336 | −2.6263 | 2.05E–13 |
| AC020907.1 | ENSG00000179066 | 3.8949 | 3.35E–03 | KCNQ1-AS1 | ENSG00000229414 | 2.53016 | 6.52E–03 |
| AC064836.2 | ENSG00000272966 | 2.5934 | 4.09E–03 | KCNQ1OT1 | ENSG00000269821 | 2.0209 | 1.35E–05 |
| AC084262.1 | ENSG00000260253 | 3.2217 | 4.57E–03 | LIFR-AS1 | ENSG00000244968 | −2.3659 | 2.13E–13 |
| AC110491.1 | ENSG00000261292 | −4.8260 | 3.22E–22 | LINC00092 | ENSG00000225194 | −2.8438 | 8.99E–30 |
| ADAMTS9-AS1 | ENSG00000241158 | −3.9253 | 2.66E–28 | LINC00330 | ENSG00000235097 | −2.9422 | 1.32E–07 |
| ADAMTS9-AS2 | ENSG00000241684 | −2.8713 | 5.15E–21 | LINC00402 | ENSG00000235532 | −2.7266 | 1.25E–09 |
| AGAP11 | ENSG00000271880 | −2.1666 | 1.83E–07 | LINC00460 | ENSG00000233532 | 6.2479 | 1.30E–08 |
| AL138995.1 | ENSG00000277763 | −2.4069 | 1.42E–17 | LINC00461 | ENSG00000245526 | −2.9817 | 1.73E–13 |
| AL161431.1 | ENSG00000275216 | 5.7502 | 7.72E–07 | LINC00473 | ENSG00000223414 | −3.3201 | 6.64E–17 |
| AL360004.1 | ENSG00000196979 | −2.3594 | 1.39E–06 | LINC00484 | ENSG00000229694 | −3.1173 | 2.08E–16 |
| AL512652.1 | ENSG00000275485 | 2.02862 | 2.74E–04 | LINC00488 | ENSG00000214381 | −3.1742 | 1.39E–10 |
| AL513123.1 | ENSG00000236347 | 3.0582 | 5.80E–05 | LINC00507 | ENSG00000256193 | −4.1785 | 5.34E–24 |
| AL590483.1 | ENSG00000229960 | 2.8803 | 7.85E–06 | LMO7-AS1 | ENSG00000261105 | 2.4135 | 6.21E–05 |
| AP000553.1 | ENSG00000272954 | 3.3636 | 2.14E–05 | MIR22HG | ENSG00000186594 | −2.0251 | 9.64E–22 |
| AP002478.1 | ENSG00000266401 | 4.3909 | 1.13E–04 | MYO16-AS1 | ENSG00000236242 | 3.8592 | 6.26E–03 |
| AP004609.1 | ENSG00000245869 | −2.0890 | 7.59E–05 | PCAT1 | ENSG00000253438 | 2.4776 | 4.83E–07 |
| C17orf77 | ENSG00000182352 | 4.1557 | 1.43E–03 | POU6F2-AS1 | ENSG00000224122 | 5.8205 | 4.29E–03 |
| C20orf166-AS1 | ENSG00000174403 | −3.4682 | 8.37E–20 | PVT1 | ENSG00000249859 | 2.6328 | 2.82E–18 |
| C2orf48 | ENSG00000163009 | 2.2264 | 3.27E–05 | PWRN1 | ENSG00000259905 | −2.2617 | 1.55E–04 |
| C7orf69 | ENSG00000136275 | 3.2131 | 9.71E–03 | RBMS3-AS3 | ENSG00000235904 | −2.7161 | 1.60E–13 |
| CLDN10-AS1 | ENSG00000223392 | 4.5630 | 6.72E–04 | SFTA1P | ENSG00000225383 | −2.7508 | 1.59E–11 |
| CRNDE | ENSG00000245694 | 4.4129 | 1.47E–12 | ST7-OT4 | ENSG00000214188 | 2.4463 | 6.43E–04 |
| DLX6-AS1 | ENSG00000231764 | 4.3820 | 1.38E–03 | UCA1 | ENSG00000214049 | 3.9110 | 1.06E–04 |
| EGOT | ENSG00000235947 | 2.3163 | 2.49E–03 | WASIR2 | ENSG00000231439 | 2.1913 | 8.49E–03 |
Abbreviations: FDR, false discovery rate; log2FC, log2fold change.